Rapport Therapeutics (RAPP) Amortization of Deferred Charges (2023 - 2026)
Rapport Therapeutics' (RAPP) quarterly Amortization of Deferred Charges came in at $582000.0 in Q1 2026, up 41.61% year-on-year from $411000.0 in Q1 2025, and up 1.93% on a QoQ basis from $571000.0 in Q4 2025.
Rapport Therapeutics (RAPP) Amortization of Deferred Charges (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has 4 years of Amortization of Deferred Charges data on file, last reported at $582000.0 in Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 41.61% year-over-year to $582000.0 in Q1 2026; TTM through Mar 2026 was $2.2 million, a 145.6% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, up 216.51% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $582000.0, up from $571000.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for RAPP reached as high as $582000.0 in Q1 2026 and fell as low as $154000.0 in Q4 2023.
- Historically, Amortization of Deferred Charges has averaged $341000.0 across 4 years, with a median of $288000.0 in 2024.
- Across the five-year window, Amortization of Deferred Charges advanced 7.14% in 2024 and jumped 250.0% in 2025, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $154000.0 in 2023, then gained by 7.14% to $165000.0 in 2024, then soared by 246.06% to $571000.0 in 2025, then rose by 1.93% to $582000.0 in 2026.
- Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $582000.0 in Q1 2026, $571000.0 in Q4 2025, and $567000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Rapport Therapeutics | 1.95 Bn | 1.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 582,000.00 |
| Mar 31, 2026 | 582,000.00 |
| Dec 31, 2025 | 571,000.00 |
| Dec 31, 2025 | 571,000.00 |
| Sep 30, 2025 | 567,000.00 |
| Sep 30, 2025 | 567,000.00 |
| Jun 30, 2025 | 483,000.00 |
| Jun 30, 2025 | 483,000.00 |
| Mar 31, 2025 | 411,000.00 |
| Mar 31, 2025 | 411,000.00 |
| Dec 31, 2024 | 165,000.00 |
| Dec 31, 2024 | 165,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Jun 30, 2024 | 159,000.00 |
| Jun 30, 2024 | 159,000.00 |
| Mar 31, 2024 | 156,000.00 |
| Mar 31, 2024 | 156,000.00 |
| Dec 31, 2023 | 154,000.00 |
| Dec 31, 2023 | 154,000.00 |